P378 Early hs-CRP normalization and mucosal healing are effective predictors for 1-year mucosal healing
J. Tang*, X. Gao, M. Zhi, P. Hu
The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China
High sensitive C reactive protein (hs-CRP) and mucosal healing are effective predictors for Crohn`s disease(CD). We evaluated the predictive validity of hs-CRP and mucosal healing after induction for one-year mucosal healing.
Consecutive CD patients who initiating a sheiduled infliximab therapy(5 mg/kg at week 0, 2, 6 and every 8 weeks thereafter) were enrolled. Hs-CRP was tested before each infliximab injection. Simple endoscopic scores for Crohn’s disease (SES-CD) at 14wk and 52wk were evaluated by 2 experienced endoscopists. Mucosal healing was defined as SES-CD 0-2.
39 patients with an average age of 26.23 ± 5.27yrs were prospectively enrolled in this study. Hs-CRP at 0,2,6,14wk were 9.44 ± 5.13, 3.87 ± 4.67, 3.02 ± 3.91, 5.64 ± 5.48mg/l, respectively. hs-CRP at week 6was related with mucosal healing at one year, while there were no obvious relationship between hs-CRP at 0,2,14 wk. ROC curve indicated that for a hs-CRP cut-off of 1.65mg/l, the sensitivity for predicting one-year mucosal healing was 83% and the specificity was 62% (area under curve [AUC], 0.76; P<0.01). 21 patients achieved mucosal healing at week14. 86% (18/21) of them maintained a sustaining mucosal healing at 52wk. Logistic regression analysis showed positive relationship between mucosal healing at 14wk and at 52wk (P=0.01).
Early hs-CRP normalization and mucosal healing are effective predictors for one-year mucosal healing in CD patients undergoing infliximab therapy.
undergoing infliximab therapy.